Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers

[1]  喬 嶋本.  Nested Case-control Study , 1992, Definitions.

[2]  V. Roggli,et al.  Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure , 2018, Carcinogenesis.

[3]  T. Brüning,et al.  Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population , 2018, International journal of medical sciences.

[4]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[5]  G. Zalcman,et al.  Immunotherapy in relapsed mesothelioma. , 2018, Immunotherapy.

[6]  S. Armato,et al.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.

[8]  S. Moebus,et al.  Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study , 2017, BMJ Open.

[9]  M. Yokoo,et al.  Estimation of the global burden of mesothelioma deaths from incomplete national mortality data , 2017, Occupational and Environmental Medicine.

[10]  K. Pantel,et al.  Characterization of single circulating tumor cells , 2017, FEBS letters.

[11]  H. Pass,et al.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. , 2017, Translational lung cancer research.

[12]  T. Brüning,et al.  Calretinin as a blood-based biomarker for mesothelioma , 2017, BMC Cancer.

[13]  Xianglei He,et al.  Serum HMGB1 as a Potential Biomarker for Patients with Asbestos-Related Diseases , 2017, Disease markers.

[14]  S. Landi,et al.  A Novel Panel of Serum Biomarkers for MPM Diagnosis , 2017, Disease markers.

[15]  I. Jacobs,et al.  Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples , 2017, British Journal of Cancer.

[16]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma , 2017 .

[17]  T. Brüning,et al.  Incidence of malignant mesothelioma in Germany 2009–2013 , 2017, Cancer Causes & Control.

[18]  T. Brüning,et al.  Incidence of malignant mesothelioma in Germany 2009–2013 , 2016, Cancer Causes & Control.

[19]  Sharyn I. Katz,et al.  Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group. , 2016, Lung cancer.

[20]  I. Pastan,et al.  Mesothelin Immunotherapy for Cancer: Ready for Prime Time? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Y. Takeshima,et al.  Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion. , 2016, European journal of radiology.

[22]  J. Peto,et al.  Consensus Report of the 2015 Weinman International Conference on Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[24]  A. Musk,et al.  ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4–10 years in advance of clinical symptoms , 2016, Clinical Proteomics.

[25]  A. Guermazi,et al.  Results from a Population-based Cohort Study Detect Early Onset and Progression of Articular Cartilage Degeneration : Ability of a Urine Assay of Type II Collagen Cleavage by Collagenases to , 2016 .

[26]  John F. Timms,et al.  Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset , 2015, BioMed research international.

[27]  J. Rantanen,et al.  Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. , 2015, Scandinavian journal of work, environment & health.

[28]  T. Brüning,et al.  Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis , 2014, PloS one.

[29]  T. Brüning,et al.  Biomarker research with prospective study designs for the early detection of cancer. , 2014, Biochimica et biophysica acta.

[30]  R. Brand,et al.  Prediagnostic Serum Biomarkers as Early Detection Tools for Pancreatic Cancer in a Large Prospective Cohort Study , 2014, PloS one.

[31]  J. Creaney,et al.  Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. , 2013, Lung cancer.

[32]  Xiaomin Dong,et al.  Identification of Novel Autoantibodies for Detection of Malignant Mesothelioma , 2013, PloS one.

[33]  H. Dienemann,et al.  Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[35]  Y. Lotan,et al.  Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines , 2013, International Archives of Occupational and Environmental Health.

[36]  Deborah H Yates,et al.  A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels , 2012, Clinical chemistry and laboratory medicine.

[37]  Stephen A. Williams,et al.  Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.

[38]  K. Nackaerts,et al.  Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Adami,et al.  Suicide and cardiovascular death after a cancer diagnosis. , 2012, The New England journal of medicine.

[40]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[41]  Arsenic, metals, fibres, and dusts. , 2012, IARC monographs on the evaluation of carcinogenic risks to humans.

[42]  J. Creaney,et al.  Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening. , 2011, Lung cancer.

[43]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[44]  S. Vansteelandt,et al.  Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  S. Plevritis,et al.  Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model , 2011, Cancer Causes & Control.

[46]  K. Schillinga,et al.  A prospective longitudinal cohort study , 2011 .

[47]  A. Weber,et al.  Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos , 2011, Archives of Toxicology.

[48]  Jennifer D. Brooks,et al.  DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. , 2010, Cancer epidemiology.

[49]  S. Skates,et al.  Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[50]  T. Brüning,et al.  Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum , 2010, Biomarker insights.

[51]  T. Brüning,et al.  Open Access Technical Advance Development of an Enzyme-linked Immunosorbent Assay for the Detection of Human Calretinin in Plasma and Serum of Mesothelioma Patients , 2022 .

[52]  J. V. van Meerbeeck,et al.  Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. , 2009, Clinical chemistry.

[53]  H. Pass,et al.  Current status of screening for malignant pleural mesothelioma. , 2009, Seminars in thoracic and cardiovascular surgery.

[54]  N. Paul,et al.  Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  S. Lundgren,et al.  Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. , 2008, Lung cancer.

[56]  R. Tumino,et al.  Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. , 2007, European journal of cancer.

[57]  A. Cipriani,et al.  What is an individual patient data meta-analysis? , 2007, Epidemiologia e Psichiatria Sociale.

[58]  N. Sardesai,et al.  MESOMARK: a potential test for malignant pleural mesothelioma. , 2007, Clinical chemistry.

[59]  T. Brüning,et al.  Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. , 2007, Cancer biomarkers : section A of Disease markers.

[60]  Alan T. Remaley,et al.  Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer , 2006, Clinical Cancer Research.

[61]  A. Musk,et al.  Mesothelin-family proteins and diagnosis of mesothelioma , 2003, The Lancet.

[62]  K. Johnson.  An Update. , 1984, Journal of food protection.

[63]  V. Rush,et al.  Asbestos , 1896, The Lancet.

[64]  A. Frank.  IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos. , 1977, IARC monographs on the evaluation of the carcinogenic risk of chemicals to man.

[65]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[66]  W. Kröger,et al.  Recommendations , 1915, Nature.